Biotech Values

[DewDiligence]

ASMB/ENTA—[JT] seems to be questioning the whole HBsAg theory.

I would say JT is questioning the notion that one can obtain a functional cure in HBV by modulating the immune system, and I share such skepticism (as noted in some prior posts on this board).

If an immune-modulated functional cure is not attainable, it’s bullish rather than bearish for such companies as ENTA and ASBM, who are developing (small-molecule) direct-viral inhibitors.

p.s. HBsAg has little to with this discussion, IMO. It’s more of a disease biomarker than a cause of chronic infection.